Stock Detail
IDENIX PHARMACEUTICALS INC
Sector: Biotechnology
Latest Quote @ Sat May 5 07:51:17 (15 min delayed)
| N/A |
N/A |
$4.31 |
+0.12 |
2.86% |
1.03M |
Last Day's Data
| $4.31 |
$4.47 |
$0.12 |
2.86% |
0.00 |
$4.19 |
| $4.17 |
$4.12 |
1.00 |
577.36M |
811,833.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 4.65 |
4.48 |
4.30 |
4.13 |
3.95 |
Stock Profile
Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of human viral and other infectious diseases. It primarily focuses on the treatment of infections caused by hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). The company's HBV product candidates include telbivudine for the treatment of an inflammatory liver disease associated with chronic HBV infection; and valtorcitabine, which is in phase IIb clinical trial. Idenix also develops valopicitabine or NM283 for the treatment of HCV, as well as a product candidate from the class of compounds known as nonnucleoside reverse transcriptase inhibitors for the treatment of HIV. Its Telbivudine product candidate is in phase III clinical trial, and valopicitabine or NM283 product candidate is in phase IIb clinical trial. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts. Idenix Pharmaceuticals, Inc. is a subsidiary of Novartis Pharma AG.
